Clinical trial
Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to…
NCT00421187 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT00421187 |
|---|---|
| Title | Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics |
| Official title | Phase III Study of 3 Sequential Doses (10 mg/kg, 5 mg/kg, and 5 mg/kg) vs 3 mg/kg/Day of AmBisome® in the Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Febrile Neutropenia |
| Intervention type | Drug |
| Interventions | Liposomal amphotericin B (AmBisome®) |
| Enrollment | 20 |
| Start date | Mar 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jan 11, 2007 |
| Last update posted | Mar 11, 2011 |
| Countries | Greece |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: